ICON plc Q1 FY2025 earnings call

• Market perspective: Cautious optimism with mixed dynamics in biotech (elevated opportunities but more cancellations) and large pharma (muted RFP but high success rate).
• Business development: Biotech had increased opportunities but more RFP cancellations; large pharma had muted RFP but strong partnership positioning.
• Operational performance: Revenue impacted by delayed next gen COVID vaccine study; adjusted EBITDA margin 19.5% due to good cost control; focus on driving operational utilization.
• AI tools: Launched iSubmit (automates clinical trial doc management) and SmartDraft (streamlines clinical contract drafting).
• Capital deployment: Repurchased $250 million in shares in Q1, evaluating strategic M&A.

Revenue in Q1 was $2 billion, a year-on-year decrease of minus 4.3% or minus 3.2% on a constant currency basis. Adjusted EBITDA was $390.7 million for the quarter, or 19.5% of revenue. Adjusted gross margin was 28.2% compared to 29.9% in Q1 2024. Adjusted SG&A expense was $173.4 million in Q1, or 8.7% of revenue. Cash from operating activities in the quarter was $268.2 million and free cash flow was $239.3 million. Top 25 customers represented 64% of revenue, with top 5 at 24.9% and top 10 at 40.2%.

• Updated full year guidance reflects elevated cancellations and removal of $350 million from two next gen COVID trials. Book-to-bill was 1.01 in Q1, expecting continued volatility in bookings. Burn rate expected to remain around Q1 levels. The midpoint of revenue guidance incorporates positive news on one of the COVID trials restarting.

• Elevated cancellations due to portfolio prioritization, clinical data futility decisions, etc.
• Volatility in bookings due to cautious customer reprioritizations.
• Macro uncertainty affecting biotech funding and large pharma budget spend.

Q: About elevated cancellations, any outlier or sizable ones?

A: No, cancellations were across segments reflecting portfolio distribution. Expected to continue elevated.

Q: On overall backdrop, cancellations similar to last quarter, thoughts on positives/negatives?

A: Cancellations ticked up, expect continued elevated levels, may tick up in Q2 due to a large cancellation. Book-to-bill 1.01, expecting sustained elevated cancellations.

Q: On revenue, customers price sensitive, RFP noise, win rate?

A: Biotech has lower win rate due to more competition; pharma win rates healthy. Adjusting expectations for biotech RFP flow but not treating differently.

Q: On large pharma cycle, partnerships, M&A?

A: Large pharma focused on cost reduction, will need to spend on R&D/acquisitions. Outsourcing viable due to uncertainty, well positioned for large pharma's future spending.

Q: On tariffs, impact on ICON?

A: Minor impact on services; lab kits could be affected but minor. Pharma tariffs uncertain, delays noted, impact unclear.

Q: On FSO vs FSP mix, changes?

A: Mix relatively steady; FSP growing slightly faster. Blending of FSO/FSP in large alliances, mid-sized customers nibbling at FSP but no major shifts.

Q: On margins, EBITDA target, cadence?

A: EBITDA margin expected to gradually increase from Q1's 19.5%, exiting year close to 21% as in Q4 2024.

Q: On China clinical development, positioning?

A: Well positioned in China with 1200+ employees; optimistic about R&D opportunities in China.

Q: On full year guide, conservatism, COVID work?

A: Guidance range reflects macro environment, cautious view. Positive news on one COVID trial restarting provides reassurance.

Q: On margins, pricing, FSP mix, growth needed?

A: No radical change in pricing; expect operating leverage as revenue grows, managing cost base prudently.

Q: On COVID work removal from outlook, revenue impact?

A: $350 million was anticipated 2025 revenue, adjusted in guidance. Two studies, aggregate impact on revenue range.

Q: On trends with largest customers?

A: Some downtick in top customers, movement within top 10, focusing on strategic partnerships.

Q: On 2Q book-to-bill, month-over-month trends?

A: Early to call Q2 book-to-bill; no month-over-month trend extrapolation, guidance assumes consistent conditions.

Q: On guide reduction, variables?

A: Guidance range accounts for $350 million COVID impact, FX tailwind, book-to-bill, burn rate, and current visibility.